- Home
- |
- Contact
- |
- Pharmacovigilance
- |
Welcome to
Chiesi group
Foster is a fixed combination of beclomethasone dipropionate (corticosteroid) and formoterol fumarate (a long-acting β2-agonist with rapid onset of effect) to be taken by inhalation. In 2006 the drug was approved for the maintenance therapy of asthma; after its first launch in Germany on October 2006, it is now sold in over 35 countries worldwide, including Russia and China. Further launches are planned throughout 2014.
About Chiesi Farmaceutici S.p.A
Chiesi Farmaceutici is a research-focused international group, with more than 75 years of experience headquartered in Parma (Italy). Chiesi researches, develops and commercializes innovative pharmaceutical solutions in the respiratory therapeutics and specialist medicine areas. In 2013, Chiesi achieved sales of over 1.2 billion Euros, constituting double digit growth over 2012. Its R&D centers in Parma (Italy), Paris (France), Rockville (USA), Chippenham (UK) and the R&D team of the newly-acquired Danish company Zymenex, integrate their efforts to advance Chiesi's pre-clinical, clinical and registration programs. The Chiesi Group employs approximately 3900 people, 480 of which are dedicated to R&D activities. For more information, please visit www.chiesi.com.
